Solid Tumors Clinical Trials in Durham, North Carolina

5 studies are recruiting for solid tumors in Durham, North Carolina right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)

   The purpose of this study is to evaluate the long-term safety and efficacy of pembrolizumab (MK-3475) in participants from previous Merck pembrolizumab-based parent studies who transition into this extension study. This study will consist of three phases: 1) First Course Phase, 2) Survival Follow-u…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Duke Cancer Center ( Site 0028), Durham, North Carolina

   Locations

   782 in total

   Run by

   Merck Sharp & Dohme LLC

   See if you can join NCT03486873 on ClinicalTrials.gov

2. A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)

   This is an open-label, multicenter Phase 2 study evaluating BMS-986504 in participants with advanced and/or metastatic solid tumors that have MTAP deletion. The study includes a monotherapy component and a combination component in which BMS-986504 is given with other anti-cancer agents. The trial w…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Local Institution - 0100, Durham, North Carolina

   Locations

   58 in total

   Run by

   Bristol-Myers Squibb

   See if you can join NCT07492680 on ClinicalTrials.gov

3. Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration

   The purpose of this study is to establish the recommended Phase 2 dose (RP2D) and/or maximum tolerated dose (MTD), safety, pharmacokinetics (PK), pharmacodynamics (PD), and antitumor activity of ORIC-114 as a Single Agent or in Combination with Chemotherapy when administered to patients with advanc…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Duke Cancer Institute, Durham, North Carolina

   Locations

   42 in total

   Run by

   ORIC Pharmaceuticals

   See if you can join NCT05315700 on ClinicalTrials.gov

4. QTX3034 in Patients With KRAS G12D Mutation

   Phase 1 study to determine the safety and tolerability of QTX3034 as a single agent or in combination with cetuximab.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Duke University, Durham, North Carolina

   Locations

   14 in total

   Run by

   Quanta Therapeutics

   See if you can join NCT06227377 on ClinicalTrials.gov

5. The FLOTILLA Study: Providing Continued Access to The Study Medicines Encorafenib and Binimetinib for Participants in Prior Clinical Trials

   The purpose of this clinical trial (called the FLOTILLA study) is to give continued access to the study medicines, as well as safety follow-up, for participants in prior clinical trials of encorafenib and/or binimetinib. All participants who took part in earlier encorafenib and/or binimetinib studi…

   Stage

   Phase 4

   Ages

   18 and older

   Site

   Duke Cancer Center, Durham, North Carolina

   Locations

   67 in total

   Run by

   Pfizer

   See if you can join NCT05203172 on ClinicalTrials.gov